BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

PLoS By Category | Recent PLoS Articles
Immunology - Physiology - Rheumatology

Fc?RIIIa Expression on Monocytes in Rheumatoid Arthritis: Role in Immune-Complex Stimulated TNF Production and Non-Response to Methotrexate Therapy
Published: Tuesday, January 03, 2012
Author: Dawn L. Cooper et al.

by Dawn L. Cooper, Stephen G. Martin, James I. Robinson, Sarah L. Mackie, Christopher J. Charles, Jackie Nam, YEAR Consortium, John D. Isaacs, Paul Emery, Ann W. Morgan

Objective

The expression of Fc?RIIIa/CD16 may render monocytes targets for activation by IgG-containing immune complexes (IC). We investigated whether Fc?RIIIa/CD16 was upregulated in rheumatoid arthritis (RA), associated with TNF production in response to IC-stimulation, and if this predicted response to methotrexate therapy.

Methods

Fc?RIIIa/CD16 expression on CD14low and CD14++ monocytes was measured by flow cytometry in healthy controls and RA patients (early and long-standing disease). Intracellular TNF-staining was carried out after in vitro LPS or heat-aggregated immunoglobulin (HAG) activation. Fc?RIIIa/CD16 expression pre- and post-steroid/methotrexate treatment was examined.

Results

Increased Fc?RIIIa/CD16 expression on CD14++ monocytes in long-standing RA patients compared to controls was demonstrated (p?=?0.002) with intermediate levels in early-RA patients. HAG-induced TNF-production in RA patients was correlated with the percentage of CD14++ monocytes expressing Fc?RIIIa/CD16 (p<0.001). The percentage of CD14++ monocytes expressing Fc?RIIIa/CD16 at baseline in early DMARD-naïve RA patients was negatively correlated with DAS28-ESR improvement 14-weeks post-methotrexate therapy (p?=?0.003) and was significantly increased in EULAR non-responders compared to moderate (p?=?0.01) or good responders (p?=?0.003). Fc?RIIIa/CD16 expression was not correlated with age, presence of systemic inflammation or autoantibody titers.

Conclusion

Increased Fc?RIIIa/CD16 expression on CD14++ monocytes in RA may result in a cell that has increased responsiveness to IC-stimulation. This monocyte subset may contribute to non-response to methotrexate therapy.

  More...

 

//-->